Compare Recursion Pharmaceuticals Inc (RXRX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ProShares UltraPro QQQ ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while ProShares UltraPro QQQ ETF trades at $71.24. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | TQQQ | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $87.22 |
52-Week Low | $2.84 | $37.89 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.16, down 0.29% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights its amplified returns during the AI boom but warns of structural costs like volatility decay. The ETF's performance is closely tied to large-cap tech earnings and market sentiment.
The outlook for TQQQ hinges on continued tech sector strength, particularly AI-driven growth, but risks include high volatility and decay from daily rebalancing. Investors face amplified gains or losses, making it suitable only for those comfortable with significant risk. Monitoring underlying index performance and tech earnings is critical for timing entries and exits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
